(2,3-dimethylphenyl)(4-methyl-4,5-dihydro-3H-pyrrol-2-yl)amine hydrochloride | 1404051-96-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2,3-dimethylphenyl)(4-methyl-4,5-dihydro-3H-pyrrol-2-yl)amine hydrochloride
• 英文别名: N-(2,3-dimethylphenyl)-3-methyl-3,4-dihydro-2H-pyrrol-5-amine;hydrochloride
• CAS: 1404051-96-2
• 化学式: C₁₃H₁₈N₂*ClH
• 分子量: 238.76
• InChiKey: RXYHPPZJPWYRFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.58
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  24.4
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,3-二甲基苯胺 、 4-甲基-2-吡咯烷酮 在 三氯氧磷 、 盐酸 作用下， 以 二氯甲烷 、 乙醇 为溶剂， 反应 6.0h， 以40%的产率得到(2,3-dimethylphenyl)(4-methyl-4,5-dihydro-3H-pyrrol-2-yl)amine hydrochloride
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 2-Aryliminopyrrolidines as Selective Ligands for I₁ Imidazoline Receptors: Discovery of New Sympatho-Inhibitory Hypotensive Agents with Potential Beneficial Effects in Metabolic Syndrome

  摘要：

  New 2-aryliminopyrrolidines (1-18) were synthesized and tested for their binding properties on I-1 imidazoline receptors vs a2-adrenergic receptors and their blood pressure effects after both systemic and intracerebral administrations. The purposes of this study were: (i) to analyze structureactivity and affinity relationships on I-1 imdazoline receptors and (ii) to propose some leader compounds for the development of new sympatho-inhibitory drugs with potential applications in hypertension and/or metabolic syndrome, i.e., a cluster of cardiovascular (hypertension) and metabolic disorders. Our study highlights decisive arguments of SAR concerning both the affinity for I(1)Rs and the hypotensive activity of 2-aryliminopyrrolidines. Binding assays showed high affinity and selectivity of some compounds for I-1 imidazoline receptors over alpha(2)-adreergic receptors. Compound 13 (laboratory reference LNP599; K-i = 3.2 nM on I(1)imidazoline receptors) is the prototype for the development of new centrally acting agents targeting specifically I(1)imidazoline receptors to be used in the management of hypertension and/or metabolic syndrome.

  DOI：

  10.1021/jm501456p

文献信息

• NOVEL AMINO-PYRROLINE DERIVATIVES, AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF METABOLIC SYNDROME
  申请人：Bousquet Pascal

  公开号：US20140045910A1

  公开（公告）日：2014-02-13

  Novel amino-pyrrolinic derivatives, their pharmacologically acceptable salts and use thereof in the prevention and/or treatment of metabolic syndrome.

  新型氨基吡咯烷衍生物，其药理学上可接受的盐和在预防和/或治疗代谢综合征中的应用。
• US9303019B2
  申请人：——

  公开号：US9303019B2

  公开（公告）日：2016-04-05
• Synthesis and Biological Evaluation of 2-Aryliminopyrrolidines as Selective Ligands for I₁ Imidazoline Receptors: Discovery of New Sympatho-Inhibitory Hypotensive Agents with Potential Beneficial Effects in Metabolic Syndrome
  作者：Vincent Gasparik、Hugues Greney、Stephan Schann、Josiane Feldman、Lyne Fellmann、Jean-Daniel Ehrhardt、Pascal Bousquet

  DOI：10.1021/jm501456p

  日期：2015.1.22

  New 2-aryliminopyrrolidines (1-18) were synthesized and tested for their binding properties on I-1 imidazoline receptors vs a2-adrenergic receptors and their blood pressure effects after both systemic and intracerebral administrations. The purposes of this study were: (i) to analyze structureactivity and affinity relationships on I-1 imdazoline receptors and (ii) to propose some leader compounds for the development of new sympatho-inhibitory drugs with potential applications in hypertension and/or metabolic syndrome, i.e., a cluster of cardiovascular (hypertension) and metabolic disorders. Our study highlights decisive arguments of SAR concerning both the affinity for I(1)Rs and the hypotensive activity of 2-aryliminopyrrolidines. Binding assays showed high affinity and selectivity of some compounds for I-1 imidazoline receptors over alpha(2)-adreergic receptors. Compound 13 (laboratory reference LNP599; K-i = 3.2 nM on I(1)imidazoline receptors) is the prototype for the development of new centrally acting agents targeting specifically I(1)imidazoline receptors to be used in the management of hypertension and/or metabolic syndrome.